JP2017524743A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524743A5
JP2017524743A5 JP2017528767A JP2017528767A JP2017524743A5 JP 2017524743 A5 JP2017524743 A5 JP 2017524743A5 JP 2017528767 A JP2017528767 A JP 2017528767A JP 2017528767 A JP2017528767 A JP 2017528767A JP 2017524743 A5 JP2017524743 A5 JP 2017524743A5
Authority
JP
Japan
Prior art keywords
bioactive agent
composition
matrix
composition according
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017528767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524743A (ja
JP6910949B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/045402 external-priority patent/WO2016025911A1/en
Publication of JP2017524743A publication Critical patent/JP2017524743A/ja
Publication of JP2017524743A5 publication Critical patent/JP2017524743A5/ja
Application granted granted Critical
Publication of JP6910949B2 publication Critical patent/JP6910949B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017528767A 2014-08-14 2015-08-14 タンパク質を安定化させ、送達するための組成物 Active JP6910949B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462037492P 2014-08-14 2014-08-14
US62/037,492 2014-08-14
PCT/US2015/045402 WO2016025911A1 (en) 2014-08-14 2015-08-14 Compositions for stabilizing and delivering proteins

Publications (3)

Publication Number Publication Date
JP2017524743A JP2017524743A (ja) 2017-08-31
JP2017524743A5 true JP2017524743A5 (cg-RX-API-DMAC7.html) 2018-09-27
JP6910949B2 JP6910949B2 (ja) 2021-07-28

Family

ID=54011102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017528767A Active JP6910949B2 (ja) 2014-08-14 2015-08-14 タンパク質を安定化させ、送達するための組成物

Country Status (6)

Country Link
US (2) US10722468B2 (cg-RX-API-DMAC7.html)
EP (1) EP3179985A1 (cg-RX-API-DMAC7.html)
JP (1) JP6910949B2 (cg-RX-API-DMAC7.html)
AU (1) AU2015301399B2 (cg-RX-API-DMAC7.html)
CA (1) CA2957966C (cg-RX-API-DMAC7.html)
WO (1) WO2016025911A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102218427B1 (ko) 2017-09-20 2021-02-22 차의과학대학교 산학협력단 단백질 약물을 포함하는 코아세르베이트 조성물 및 이를 포함하는 창상 치료제
KR101883142B1 (ko) * 2017-10-30 2018-07-30 아주대학교산학협력단 Sdf1을 유효성분으로 포함하는 피부 색소 형성 조절용 조성물 또는 피부 미백용 조성물
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2020028907A1 (en) 2018-08-03 2020-02-06 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
US12186590B2 (en) 2018-10-19 2025-01-07 University Of Rochester Immune modulators in combination with radiation treatment for advanced pancreatic cancer
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
EP4464339A4 (en) * 2022-01-13 2026-08-05 Nat Cancer Ct BIOCOMPATIBLE COMPOSITION FOR MARKING A TARGET LESION, AND ITS PREPARATION PROCESS

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929406A (en) 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
GB929401A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
GB969808A (en) 1962-06-08 1964-09-16 Boots Pure Drug Co Ltd Anthelmintic compositions and compounds
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
GB9506946D0 (en) * 1995-04-04 1995-05-24 Univ Strathclyde Microgels
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6025393A (en) * 1995-09-25 2000-02-15 Santen Pharmaceutical Co., Ltd. Method for treatment of inflammatory intestinal diseases
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
DE69930753D1 (de) 1998-09-01 2006-05-18 Elan Corp Plc Dublin Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff-zusammensetzungen dazu
JP2003519651A (ja) * 2000-01-14 2003-06-24 ブラウン ユニバーシティ リサーチ ファウンデーション 微紛化凍結乾燥粒子
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US20020106406A1 (en) * 2000-12-08 2002-08-08 Mchugh Anthony J. Crystallizable/non-crystallizable polymer composites
JP2005500304A (ja) * 2001-06-21 2005-01-06 アルタス バイオロジックス インコーポレイテッド 球状タンパク質粒子およびそれらの作製方法および使用方法
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
CA2522957C (en) * 2003-04-23 2013-10-22 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
US20080124400A1 (en) * 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
US20060228352A1 (en) 2005-02-24 2006-10-12 Schoenberger Stephen P TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
CA2639921C (en) 2006-01-23 2014-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Microspheres comprising nanocapsules containing a lipophilic drug
US20100210792A1 (en) 2006-12-05 2010-08-19 David Taft Drug delivery
JP4621218B2 (ja) 2007-02-09 2011-01-26 有限会社バイオ研 Th1誘導剤及びその製造方法
US9814553B1 (en) * 2007-10-10 2017-11-14 Abbott Cardiovascular Systems Inc. Bioabsorbable semi-crystalline polymer for controlling release of drug from a coating
US20090202642A1 (en) * 2008-02-08 2009-08-13 Xiao Huang Drug Delivery System Comprising Microparticles and Gelation System
AU2009214307A1 (en) 2008-02-13 2009-08-20 Bayer Intellectual Property Gmbh Drug delivery system with stabilising effect
US8673359B2 (en) 2010-07-08 2014-03-18 Brown University Nanoparticle compositions and methods for improved oral delivery of active agents
WO2012018616A2 (en) 2010-07-26 2012-02-09 Anaphore, Inc. Polypeptides that bind trail-r1 and trail-r2
US20130101553A1 (en) 2011-04-18 2013-04-25 The Regents Of The University Of California Inducing inactivation of fibrogenic myofibroblasts
CA2842514C (en) * 2011-07-22 2018-12-18 Innocore Technologies B.V. Biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymers for controlled release of biologically active compounds
US10765634B2 (en) 2012-01-24 2020-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Controlled release formulations for the induction and proliferation of blood cells

Similar Documents

Publication Publication Date Title
JP5649783B2 (ja) Hcvプロドラッグ処方
JP5167345B2 (ja) 薬剤を加速放出する腸溶コーティングを含む固体剤形
CN101321517B (zh) 能够口服和活性成分快速释放的固体药物剂型
Tawfeek et al. Colonic delivery of indometacin loaded PGA-co-PDL microparticles coated with Eudragit L100-55 from fast disintegrating tablets
KR101799625B1 (ko) 제약 또는 기능식품 투여 형태에 적합한 코팅 조성물
Marquette et al. Stability study of full-length antibody (anti-TNF alpha) loaded PLGA microspheres
JP6910949B2 (ja) タンパク質を安定化させ、送達するための組成物
SI21394A2 (sl) Farmacevtske pelete, ki vsebujejo tamsulozin
EP3362052B1 (en) Processes for preparing formulations for gastrointestinal-targeted therapies
US20240408050A1 (en) Dihydromyricetin spray-dried dispersion formulations and methods for forming them
JP2006514698A (ja) ナノ粒子生物活性物質
EP1729741A2 (en) Polymeric drug delivery system for hydrophobic drugs
EP4037659B1 (en) Pharmaceutical composition comprising enzalutamide
CN112972388A (zh) 卡利拉嗪释放制剂
JP2023505714A (ja) アルカリ剤及び腸溶性コーティング層を含む剤形
Kumar et al. Solid dispersion-strategy to enhance solubility and dissolution of poorly water soluble drugs
JP2016519133A (ja) ポリマーフィルムコーティングされた医薬組成物の薬物放出プロフィールを安定化させるための方法
TW200829287A (en) Short term slow release drug delivery system
Yu et al. Design of redispersible high-drug-load amorphous formulations: impact of ionic vs nonionic surfactants on processing and performance
JP5841609B2 (ja) Hcv感染症を処置するための医薬組成物
JP5758899B2 (ja) 活性物質を含有するコーティングにより被覆されたペレット
CN101668515A (zh) 药物组合物和方法
WO2024120944A1 (en) Delayed release composition with resistance against fed state gastric conditions
CN103347931A (zh) 制备用于药物剂型的稳定保护性衣层的粉末包衣剂
CN108113976B (zh) Th-302制剂、制备方法及其用途